Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of ponatinib in subject with chronic myeloid leukaemia who are resistant to two or more prior tyrosine kinase inhibitors.

Next Previous
Trial Profile

Safety and efficacy of ponatinib in subject with chronic myeloid leukaemia who are resistant to two or more prior tyrosine kinase inhibitors.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Pearl

Most Recent Events

  • 21 Jan 2016 New trial record
  • 08 Dec 2015 Results (n=35) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top